Journal
CURRENT OPINION IN VIROLOGY
Volume 20, Issue -, Pages 34-39Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2016.08.010
Keywords
-
Categories
Funding
- Cancer Research Switzerland [KFS-3234-08-2013]
- Worldwide Cancer Research [14-1033]
- SPARKS [15UOZ01]
- KFSPMS and KFSPHHLD of the University of Zurich
- Sobek Foundation
- Swiss Vaccine Research Institute
- Swiss National Science Foundation [310030_162560, CRSII3_160708]
- Swiss National Science Foundation (SNF) [310030_162560] Funding Source: Swiss National Science Foundation (SNF)
- Sparks Charity [15UOZ01] Funding Source: researchfish
Ask authors/readers for more resources
Epstein Barr virus (EBV) is a human gamma-herpesvirus that was discovered in Burkitt's lymphoma more than 50 years ago. Since then it has been proposed as the causative agent of up to 2% of all tumors worldwide, mainly lymphomas and epithelial cell carcinomas. Surprisingly, persistent EBV infection is at the same time found in more than 90% of healthy human adults. Even the very same programs of EBV infection that are found in the associated malignancies are continuously present in healthy EBV carriers. We will discuss primary immunodeficiencies and immune compartment changes during the first decade of human life that give us insights into how tumorigenesis by persistent EBV infection and Hodgkin's lymphoma predisposing infectious mononucleosis is prevented during primary infection. These insights should allow identifying individuals at risk to develop EBV associated malignancies, who would benefit from EBV specific vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available